Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis

Bibliography

• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22(1):14-22
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342(17):1255-65
   PubMed Web of Science ®Google Scholar
• Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005;105(3):973-7
   PubMed Web of Science ®Google Scholar
• Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol 2009;82(5):329-38
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113(13):2895-901
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008;111(7):3383-7
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS-Plus: a Refined Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis that incorporates karyotype, platelet count and transfusion status. J Clin Oncol 2011;29(4):392-7
   PubMed Web of Science ®Google Scholar
• Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013;88(2):141-50
   PubMed Web of Science ®Google Scholar
• Vaidya R, Caramazza D, Finke C, et al. Circulating IL-2R, IL-8, IL-15 and CXCL10 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. ASH Annu Meet Abstr 2010;116(21):3068
   Google Scholar
• Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96(10):3374-80
   PubMed Web of Science ®Google Scholar
• Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4(4):314-22
   PubMed Web of Science ®Google Scholar
• Melchert M, List A. The thalidomide saga. Int J Biochem Cell Biol 2007;39(7-8):1489-99
   PubMed Web of Science ®Google Scholar
• Randall T. Thalidomide has 37-year history. JAMA 1990;263(11):1474
   Web of Science ®Google Scholar
• D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-5
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig TE, Rajkumar SV. Thalidomid: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 2004;22(12):2477-88
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood 2000;96(12):4007
   PubMed Web of Science ®Google Scholar
• Barosi G, Grossi A, Comotti B, et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2001;114(1):78-83
   PubMed Web of Science ®Google Scholar
• Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 2002;117(2):288-96
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002;16(9):1609-14
   PubMed Web of Science ®Google Scholar
• Merup M, Kutti J, Birgergard G, et al. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 2002;19(2):79-86
   PubMed Web of Science ®Google Scholar
• Barosi G, Elliott M, Canepa L, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Leuk Lymphoma 2002;43(12):2301-7
   PubMed Web of Science ®Google Scholar
• Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101(7):2534-41
   PubMed Web of Science ®Google Scholar
• Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004;22(3):424-31
   PubMed Web of Science ®Google Scholar
• Weinkove R, Reilly JT, McMullin MF, et al. Low-dose thalidomide in myelofibrosis. Haematologica 2008;93(7):1100-1
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108(5):1497-503
   PubMed Web of Science ®Google Scholar
• Thapaliya P, Tefferi A, Pardanani A, et al. Long term follow-up and IWG-MRT response assessment for 50 Myelofibrosis (MF) patients treated with thalidomide-prednisone based regimens. ASH Annu Meet Abstr 2010;116(21):4094
   Google Scholar
• Gupta S, Besa EC. Immunomodulatory therapy with combination of low dose thalidomide, alpha Interferon (IFN-a) and prednisone produces durable response in myelofibrosis. ASH Annu Meet Abstr 2010;116(21):4123
   Google Scholar
• Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21(2):319-30
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Miller K, et al. Direct binding with cereblon mediates the antiproliferative and immunomodulatory action of lenalidomide and pomalidomide. ASH Annu Meet Abstr 2011;118(21):738
   Google Scholar
• Basiorka AA, McGraw K, Clark J, et al. Lenalidomide upregulates erythropoietin receptor expression in hematopoietic progenitors by modulating receptor turnover. ASH Annu Meet Abstr 2011;118(21):2382
   Google Scholar
• List AF, Baker AF, Green S, et al. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control 2006;13(Suppl):4-11
   PubMedGoogle Scholar
• Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108(4):1158-64
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009;27(28):4760-6
   PubMed Web of Science ®Google Scholar
• Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010;116(22):4436-8
   PubMed Web of Science ®Google Scholar
• Jabbour E, Thomas D, Kantarjian H, et al. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 2011;118(4):899-902
   PubMed Web of Science ®Google Scholar
• Bagratuni T, Kastritis E, Roussou M, et al. Prospective evaluation of the risk of thromboembolic complications in patients treated with lenalidomide-based therapy and genetic associations. ASH Annu Meet Abstr 2011;118(21):2872
   Google Scholar
• Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol 2009;27(27):4563-9
   PubMed Web of Science ®Google Scholar
• Pardanani A, Begna K, Finke C, et al. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011;86(4):343-5
   PubMed Web of Science ®Google Scholar
• Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis (ePub 2010 ref is the same study). Leukemia 2011;25(2):301-4
   PubMed Web of Science ®Google Scholar
• Mesa RA, Pardanani AD, Hussein K, et al. Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 2010;85(2):129-30
   PubMed Web of Science ®Google Scholar
• Shastri A, Cortes JE, Jabbour EJ, et al. A phase II study of low-dose pomalidomide (0.5mg/day) and prednisone combination therapy in patients with myelofibrosis and significant anemia. ASH Ann Meet Abstr 2012;120(21):1728
   Google Scholar
• Pardanani A, Vannucchi AM, Passamonti F, et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011;25(2):218-25
   PubMed Web of Science ®Google Scholar
• Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling through the hematopoietic cytokine receptors. Ann Rev Immunol 1995;13:369-98
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia 2008;22(4):756-61
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807
   PubMed Web of Science ®Google Scholar
• Verstovsek Ram S, Gotlib JR, Levy RS. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF) [abstract 6500]. ASCO Annu Meet; 2011
   Google Scholar
• Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013;31(10):1285-92
   PubMed Web of Science ®Google Scholar
• Pardanani A, Gotlib JR, Jamieson C, et al. Longer-term follow up with TG101348 therapy in myelofibrosis confirms sustained improvement in splenomegaly, disease-related symptoms, and JAK2V617F allele burden. ASH Annual Meeting Abstracts. 2010;116(21):459
   Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117-27
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Caramazza D, George G, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis [abstract 6514]. ASCO Annu Meet; 2011
   Google Scholar
• Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. ASH Annual Meet Abstr 2011;118(21):282
   Google Scholar
• Celgene. Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence (RESUME) 2012.
   Google Scholar